K. Sandeep Prabhu

Prof. Dr. K. Sandeep Prabhu


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2008 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
HVHema Vunta
Hema Vunta
BBBenjamin J. Belda
Benjamin J. Belda
RARyan J. Arner
Ryan J. Arner
CRC. Channa Reddy
C. Channa Reddy
JHJohn P. Vanden Heuvel
John P. Vanden Heuvel
KPK. Sandeep Prabhu
K. Sandeep Prabhu

8 April 2013 in Nutrients
Verified
Journal Article
Open access
PDF file
YCYu-Chi Chen
Yu-Chi Chen
KPK. Sandeep Prabhu
K. Sandeep Prabhu
AMAndrea Mastro
Andrea Mastro
Selenium (Se) is an essential micronutrient that functions as a redox gatekeeper through its incorporation into proteins to alleviate oxidative stress in cells. Although the epidemiological data are somewhat controversial, the results of many studies suggest that inorganic and organic forms of Se negatively affect cancer progression, and that several selenoproteins, such as GPXs, also play important roles in tumor development. Recently, a few scientists have examined the relationship between Se and metastasis, a late event in cancer progression, and have evaluated the potential of Se as an anti-angiogenesis or anti-metastasis agent. In this review, we present the current knowledge about Se compounds and selenoproteins, and their effects on the development of metastasis, with an emphasis on cell migration, invasion, and angiogenesis. In the cancers of breast, prostate, colorectal, fibrosarcoma, melanoma, liver, lung, oral squamous cell carcinoma, and brain glioma, there is either clinical evidence linking selenoproteins, such as thioredoxin reductase-1 to lymph node metastasis; in vitro studies indicating that Se compounds and selenoproteins inhibited cell motility, migration, and invasion, and reduced angiogenic factors in some of these cancer cells; or animal studies showing that Se supplementation resulted in reduced microvessel density and metastasis. Together, these data support the notion that Se may be an anti-metastastatic element in addition to being a cancer preventative agent.

1 April 2007 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JCJeffrey D. Coleman
Jeffrey D. Coleman
KPK. Sandeep Prabhu
K. Sandeep Prabhu
JTJerry T. Thompson
Jerry T. Thompson
PRP. Sreenivasula Reddy
P. Sreenivasula Reddy
JPJeffrey M. Peters
Jeffrey M. Peters
John P. Vanden HeuvelJohn P. Vanden Heuvel
John P. Vanden Heuvel

23 April 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YCYu-Chi Chen
Yu-Chi Chen
KPK. Sandeep Prabhu
K. Sandeep Prabhu
ADArunangshu Das
Arunangshu Das
AMAndrea Mastro
Andrea Mastro
The survival rate for breast cancer drops dramatically once the disease progresses to the metastatic stage. Selenium (Se) is an essential micronutrient credited with having high anticancer and chemopreventive properties. In our study, we investigated if dietary Se supplementation modified breast cancer development in vivo. Three diets supplemented with sodium selenite, methylseleninic acid (MSA) or selenomethionine (SeMet), as well as a Se‐deficient and a Se‐adequate diet were fed to mice before mammary gland inoculation of 4T1.2 cells. The primary tumor growth, the numbers of cancer cells present in lungs, hearts, livers, kidneys and femurs and several proinflammatory cytokines were measured. We found that inorganic selenite supplementation provided only short‐term delay of tumor growth, whereas the two organic SeMet and MSA supplements provided more potent growth inhibition. These diets also affected cancer metastasis differently. Mice fed selenite developed the most extensive metastasis and had an increased incidence of kidney and bone metastasis. On the other hand, mice fed the SeMet diet showed the least amount of cancer growth at metastatic sites. The MSA diet also provided some protection against breast cancer metastasis although the effects were less significant than those of SeMet. The cytokine profiles indicated that serum levels of interlukin‐2, interleukin‐6, interferon γ and vascular endothelial growth factor were elevated in SeMet‐supplemented mice. There was no significant difference in tumor growth and the patterns of metastasis between the Se‐deficient and Se‐adequate groups. Our data suggest that organic Se supplementation may reduce/delay breast cancer metastasis, while selenite may exacerbate it.

1 November 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PKParisa Kalantari
Parisa Kalantari
VNVivek Narayan
Vivek Narayan
SNSathish K. Natarajan
Sathish K. Natarajan
KMKambadur Muralidhar
Kambadur Muralidhar
UGUjjawal H. Gandhi
Ujjawal H. Gandhi
KPK. Sandeep Prabhu
K. Sandeep Prabhu
Epidemiological studies suggest a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium deficiency, indicating a protective role for this anti-oxidant during HIV infection. Here we demonstrate that thioredoxin reductase-1 (TR1), a selenium-containing pyridine nucleotide-disulfide oxidoreductase that reduces protein disulfides to free thiols, negatively regulates the activity of the HIV-1 encoded transcriptional activator, Tat, in human macrophages. We used a small interfering RNA approach as well as a high affinity substrate of TR1, ebselen, to demonstrate that Tat-dependent transcription and HIV-1 replication were significantly increased in human macrophages when TR1 activity was reduced. The increase in HIV-1 replication in TR1 small interfering RNA-treated cells was independent of the redox-sensitive transcription factor, NF-κB. These studies indicate that TR-1 acts as a negative regulator of Tat-dependent transcription. Furthermore, in vitro biochemical assays with recombinant Tat protein confirmed that TR1 targets two disulfide bonds within the Cys-rich motif required for efficient HIV-1 transactivation. Increasing TR1 expression along with other selenoproteins by supplementing with selenium suggests a potential inexpensive adjuvant therapy for HIV/AIDS patients.

27 March 2009 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
UPUmamaheshwari D. Palempalli
Umamaheshwari D. Palempalli
UGUjjawal Gandhi
Ujjawal Gandhi
PKParisa Kalantari
Parisa Kalantari
HVHema Vunta
Hema Vunta
RARyan J. Arner
Ryan J. Arner
KPK. Sandeep Prabhu
K. Sandeep Prabhu
GA (gambogic acid) is a polyprenylated xanthone abundant in the resin of Garcinia morella and Garcinia hanburyi with a long history of use as a complementary and alternative medicine. The antitumour activity of GA has been well demonstrated and is thought to arise partly from the associated anti-inflammatory activity. Recent studies have indicated that the antitumour activity of GA is mediated by its ligation of TfR1 (transferrin receptor-1). Since the cellular expression of TfR1 is down-regulated by LPS (lipopolysaccharide), we hypothesized that an alternative pathway exists in immune cells, such as macrophages, where GA could mitigate the expression of pro-inflammatory genes. Here we demonstrate that GA inhibits the LPS-dependent expression of NF-κB (nuclear factor κB) target pro-inflammatory genes in macrophages. Western immunoblot, NF-κB-luciferase reporter and gel-shift analyses revealed that GA strongly blocked the activation of NF-κB induced by LPS, whereas 9,10-dihydro-GA, which lacks the reactive α,β-unsaturated carbonyl group, was ineffective. Moreover, GA was able to decrease nuclear p65 levels in RAW264.7 macrophages, where the expression of TfR1 was down-regulated by RNA interference. in vitro kinase assays coupled with interaction studies using biotinylated GA as well as proteomic analysis demonstrated that IKKβ [IκB (inhibitory κB) kinase-β], a key kinase of the NF-κB signalling axis, was covalently modified by GA at Cys-179, causing significant inhibition of its kinase activity. Taken together, these results demonstrate the potent anti-inflammatory activity of GA.